Latest IPHA reports update at 2024-05-11: 2023 ∙ 2022 ∙ 2021

Innate Pharma S.A. IPHA

$ 2.51 -4.68%

Innate Pharma S.A. Balance Sheet 2011-2024 | IPHA

Annual Balance Sheet Innate Pharma S.A.

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-120 M	-189 M	-150 M	-96.5 M	-174 M	-151 M	-57.8 M	-36.7 M	-29.8 M	-33.4 M
Long Term Debt	-	-	-	16.9 M	14.1 M	2.03 M	2.42 M	1.05 M	1.35 M	1.5 M	1.5 M	131 K	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	105 M	-	87.2 M	95.2 M	119 M	174 M	5.29 M	6.32 M	9.57 M	18 M
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	151 M	184 M	284 M	169 M	195 M	234 M	16.1 M	15.6 M	24.9 M	33.5 M
Deferred Revenue	-	-	-	12.5 M	91.8 M	82.1 M	47.9 M	54.9 M	-	885 K	1.26 M	7.66 M	-
Retained Earnings	-	-	-	-220 M	-156 M	-135 M	-152 M	-104 M	-116 M	-110 M	-90 M	-87.1 M	-6.98 M
Total Assets	184 M	208 M	267 M	307 M	401 M	451 M	255 M	282 M	306 M	90.7 M	55.9 M	48.3 M	60.1 M
Cash and Cash Equivalents	70.6 M	84.2 M	104 M	137 M	203 M	152 M	99.4 M	-	-	-	-	-	-
Book Value	-	-	267 M	156 M	217 M	167 M	86 M	86.2 M	72.1 M	74.6 M	40.3 M	23.4 M	26.6 M
Total Shareholders Equity	-	-	-	156 M	217 M	167 M	86 M	-	-	-	-	-	-

All numbers in EUR currency

Quarterly Balance Sheet Innate Pharma S.A.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	80.2 M	-	90 M	-	106 M	-	-	-	62.1 M	-	-	-	87.2 M	-	-	-	95.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-	-	-	-	-	-	-	-	-135 M	-	-	-	-139 M	-	-	-	-104 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	267 M	-	266 M	-	307 M	-	-	-	401 M	-	-	-	451 M	-	-	-	255 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	104 M	-	104 M	-	137 M	-	132 M	-	203 M	-	-	-	152 M	-	-	-	99.4 M	-	-	-	176 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	267 M	-	266 M	-	307 M	-	-	-	401 M	-	-	-	451 M	-	-	-	255 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	107 M	-	134 M	-	156 M	-	208 M	-	217 M	-	-	-	167 M	-	-	-	99.4 M	-	-	-	86.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency